Celcuity Inc. (CELC) News
Filter CELC News Items
CELC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CELC News Highlights
- For CELC, its 30 day story count is now at 2.
- Over the past 5 days, the trend for CELC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and PAM are the most mentioned tickers in articles about CELC.
Latest CELC News From Around the Web
Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer SymposiumMINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS). The preclinical studies evaluated gedatolisib, a pan-PI3K/mTOR inhibitor, and PAM inhibitors that selectivel |
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer SymposiumMINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023. The presentation will include potency and effica |
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceMINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI HealthCONx Conference held in Miami. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 12:30 p.m. ET on Wednesday, November 29, 2023. A live webcast of the event will be available using this weblin |
Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call TranscriptCelcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It […] |
Q3 2023 Celcuity Inc Earnings CallQ3 2023 Celcuity Inc Earnings Call |
Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic DevelopmentsIncreased R&D Expenses Drive Net Loss Expansion; Cash Position Remains Strong |
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesReceived FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) for planned Phase 1b/2 clinical trialRaised $50 million in private placement sale of equityManagement to host webcast and conference call today, November 13, 2023, at 8:00 a.m. ET MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- |
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference CallMINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To part |
Celcuity To Present at Upcoming Stifel and Jefferies Investor ConferencesMINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A formal presentation at the Stifel 2023 Healthcare Conference in New York at 4:10 p.m. ET on Tuesday, November 14, 2023. A l |
Celcuity Inc. Announces $50 Million Private PlacementMINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement ... |